Rallybio Corp (RLYB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Rallybio reported revenue of $858,000, up 43.0% from $600,000 the year before. Net income was -$9.0M (a -1046.4% net margin), or -$1.59 per diluted share. Operating margin was -3853.6%. Operating activities generated -$29.8M of cash. At fiscal year end, Rallybio held $62.3M in total assets against $4.3M in total liabilities, including $31.4M of cash and equivalents.
Open the full interactive Rallybio financials → Quarterly statements, key ratios, valuation history and price charts.
Rallybio Key Stats
| Share Price | $16.72 |
|---|---|
| Market Cap | $96.9M |
| Revenue YoY Growth | +43.0% |
| 52-Week Range | $4.22 – $17.22 |
| Shares Outstanding | 5.7 million (basic, 2026 Q2) |
Rallybio Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $600,000 | $858,000 |
| Operating Income | -$45.6M | -$67.9M | -$78.9M | -$60.5M | -$33.1M |
| Pre-Tax Income | -$45.5M | -$65.6M | -$72.5M | -$55.5M | -$9.0M |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$47.0M | -$66.7M | -$74.6M | -$57.8M | -$9.0M |
| Diluted EPS | -$14.72 | -$16.72 | -$14.72 | -$10.64 | -$1.59 |
Rallybio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $212,000 | $222,000 | $212,000 | $0 |
| Net Income | $16.0M | -$5.9M | -$8.3M | $43.7M |
| Diluted EPS | $2.88 | -$1.04 | -$1.46 | $7.53 |
Rallybio Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $175.3M | $57.0M | $24.5M | $13.9M | $31.4M |
| Current Assets | $180.9M | $179.5M | $114.8M | $67.8M | $61.3M |
| Total Assets | $182.2M | $180.4M | $115.6M | $68.1M | $62.3M |
| Current Liabilities | $6.6M | $10.7M | $9.3M | $6.2M | $4.2M |
| Total Liabilities | $6.6M | $11.1M | $9.4M | $6.5M | $4.3M |
| Shareholders' Equity | $175.6M | $169.3M | $106.2M | $61.7M | $58.0M |
Rallybio Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$45.5M | -$57.3M | -$60.3M | -$49.3M | -$29.8M |
| Cash From Investing | -$2.3M | -$112.2M | $27.7M | $33.5M | $47.3M |
| Cash From Financing | $83.0M | $51.1M | $143,000 | $5.2M | $16,000 |
| Free Cash Flow | -$45.9M | -$57.3M | -$60.3M | -$49.3M | — |
Figures from Rallybio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Rallybio financials page for every line item.
Rallybio Company Profile
| Ticker | RLYB |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New Haven, Connecticut |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001739410 |
Frequently Asked Questions
What was Rallybio's revenue in fiscal 2025?
Rallybio (RLYB) reported revenue of $858,000 for fiscal 2025.
What is Rallybio's annual revenue history?
Rallybio's annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $600,000; 2025: $858,000.
What was Rallybio's net income in fiscal 2025?
Rallybio reported net income of -$9.0M for fiscal 2025.
What was Rallybio's earnings per share (EPS) in fiscal 2025?
Rallybio's diluted EPS was -$1.59 for fiscal 2025 (adjusted for any later stock splits).
What was Rallybio's revenue last quarter?
In its most recent reported quarter (2026 Q2), Rallybio reported revenue of $0.
How many shares of Rallybio are outstanding?
Rallybio reported a weighted average of 5.7 million basic shares outstanding in 2026 Q2.
What is Rallybio's market cap?
Based on its latest closing price, Rallybio (RLYB) has a market capitalization of about $96.9M.
When does Rallybio's fiscal year end?
Rallybio's fiscal year end, as registered with the SEC, is December 31.
Where is Rallybio headquartered?
Rallybio lists its business address in New Haven, Connecticut in its SEC filings.